Jennifer Le Guévelou

"Toute frontière est une convention qui n'aspire qu'à être transcendée, pour transcender les conventions il suffit simplement d'en concevoir la possibilité".

[NonsparseOncologist @5_utr]

‼️ INDIBLADE: stage II/III (cT2-4aN0-2) MIBC -> induction ipilimumab plus nivolumab -> CRT

2-year bladder-intact event-free survival is 78% (0.67−0.9) 🤩

2-year overall survival was 96% (0.91−1)

Lots of bladders can be potentially spared!

https://t.co/LzTe72GYHD

[Prof Veeru Kasi @veerukasi]

🚨 PROTEUS full results presented at #ASCO26 & copublished in @NEJM! Small benefit of adding apalutamide to ADT peri-operatively 4 high risk prostate cancer treated with surgery. We dont know if will translate to overall survival benefit & adverse effects not insignificant 🚨

[Yüksel Ürün @DrYukselUrun]

Treatment interruption in mHSPC is becoming a patient-centered question.

In A-DREAM/A032101, 41% remained treatment-free with testosterone recovery at 18 months after ADT + ARPI interruption.

For favorable responders, a treatment holiday may be reasonable.

The key question:
Can we preserve disease control while giving patients time back from treatment?

#ASCO26 @AtishChoudhury @ALLIANCE_org @DanaFarber
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

[Laura Bukavina @LauraBukavinaMD]

Broad BCG + durvalumab for HR NMIBC? The math is brutal a 4.9% absolute DFS gain at 24 mo means treating 20 patients to avoid one event but you'll harm 1 in 6 getting there (3;1yep).. 164K/patient drug cost. Uncomfortable tradeoff🙈 I would call this progress in reverse⏪ if applied indiscriminately. Invest in biomarkers and not widespread IO overtx #bladdercancer #CancerCare

[Adam B. Weiner, MD @Adam_Weiner535]

🚨 TALAPRO-3: PARP inhibition moves earlier in mHSPC

Just out in @NEJM

🧬 599 pts w/ metastatic HRR-altered hormone-sensitive #prostatecancer randomized to talazoparib + enzalutamide vs enzalutamide alone.

📉 52% reduction in risk of radiographic progression or death (HR 0.48, P<0.001). 3-year rPFS: 77% vs 56%.

🎯 Benefit was strongest in BRCA1/2-altered disease (HR 0.37), but remained significant in non-BRCA HRR alterations (HR 0.57).

⏳ Fewer patients required subsequent therapy (HR 0.51) and PSA progression was delayed (HR 0.51).

❤️‍🩹 OS trend favored talazoparib (HR 0.77), but data remain immature.

🩸 Toxicity remains the tradeoff: Grade ≥3 anemia in 51%, transfusions in 40%, and 2 treatment-related deaths.

#ASCO26 @ASCO @PCFnews @PCF_Science @neerajaiims

🔗https://t.co/kVeRwuouKz

[Fernando GomezSancha @fgomsan]

Prostate volume doesn't reliably predict obstruction — and we've known it for decades. A new open-access review in PCAN introduces a new concept: periurethral and transition-zone fibrosis is an under-recognised, untreated driver of LUTS/BPH.
The case for antifibrotics: pirfenidone, losartan, PDE5-i, even halofuginone. https://t.co/vIw1BF5CJs

[Yüksel Ürün @DrYukselUrun]

The future MIBC paradigm is moving from “one path for all” to response-adapted care.

After EV/pembro, cCR plus ctDNA/utDNA negativity may open the door to bladder preservation and surveillance.

But the key patient question is:
Can we safely spare cystectomy without compromising cure?

#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OncoAlert @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists @AndreaNecchi @apolo_andrea @ERPlimackMD

[Dr Rishabh Jain @DrRishabhOnco]

🗣️ THE 5 BIGGEST HEAD & NECK CANCER TRIALS OF #ASCO26

1️⃣ AREST (6000)
Post-op RT vs observation in early-stage OSCC
⭐ Who truly needs adjuvant RT?

2️⃣ MACE POSTOP (6002)
Metronomic adjuvant chemo in LA oral cavity SCC
⭐ Can low-dose maintenance reduce relapse?

3️⃣ Induction De-escalation in NPC (6003)
2 vs 3 cycles induction chemo before CRT
⭐ Less toxicity. Same outcomes?

4️⃣ Carboplatin vs Cisplatin in NPC (6004)
Non-inferiority frontline CRT strategy
⭐ A gentler platinum backbone?

5️⃣ NIVOPOSTOP (6001)
Impact of neck dissection extent with post-op nivolumab + CRT
⭐ How does surgery interact with IO?

#HeadAndNeckCancer #HNOnc #OncTwitter #ASCO26 #HNSCC #MedTwitter @ASCO @myesmo @esmo_open @OncoAlert

[Ricardo R Gonzalez MD @RRGonzalezMD]

Is there value in correcting bladder outlet obstruction (BOO) from BPH prior to radiation for prostate cancer🤔? There sure is. Sequencing is key. Less complications that way. Check out our new publication:
https://t.co/d8R77wIvrc

@HMethodistUro @CarlosARiverosS @RenilTitus @OlamideOmidele @UroAnnie @JohnnySuMD @DrRajSat @SocietyofBPD @UroOnc @ARRO_org @AndrewFarach @HMethodistMD

[Dr Rishabh Jain @DrRishabhOnco]

#ASCO26

Can we safely stop ADT + ARPI in selected mHSPC patients after a deep response? 👀

The phase 2 A-DREAM trial suggests that some patients may enjoy prolonged treatment-free intervals with testosterone recovery after stopping therapy.

💡 Key findings from Abstract 5004:
▪️78 pts underwent treatment interruption
▪️58% remained treatment-free at 18 months
▪️41% remained treatment-free with testosterone recovery
▪️67% recovered eugonadal testosterone levels
▪️Median follow-up: 21.2 months

⚠️ Important caveats:
▪️Single-arm phase 2 study
▪️Highly selected exceptional responders
▪️No randomized comparator
▪️Long-term survival impact unknown

Still, this opens an important conversation around:
“Do all responders need indefinite continuous therapy?”

A major quality-of-life and survivorship question in modern prostate cancer care.

📖 Full abstract in comment ⬇️

#OncoTwitter #MedTwitter #ProstateCancer #mHSPC @ASCO @OncoAlert @UroToday @larvol

[Vedang Murthy @VedangMurthy]

This trial represents a decade of work—hypothesis → design → accrual → follow-up → data lock → Presented at @ASTRO_org 2025 plenary →publication in @JCO_ASCO
https://t.co/nPBHKp9VPN

🙏 To the patients, families, clinicians, and my team: A BIG thank you.

[Shankar Siva @_ShankarSiva]

📣 #ESTRO26 - @UmbertoRicardo e2irradiate @EORTC prospective OLIGOCARE registry of SABR for oligomets. ~2500 patients, ~3500 mets.
➡️ local failure 5% at 1 year and 11% at 3 years
➡️ Colorectal cancer has higher risk of progression
➡️ minimum PTV dose correlated with outcome

We should aim to deliver high quality SABR to optimise control! #radonc

[Chris Jackson, MD, MS @Chris_JacksonMD]

Our work identifying a new spinal cord constraint for spine SBRT was published yesterday in @JAMAOnc @DanHigginsonMD.

Here, a thread:

https://t.co/exXAnNXZjK

[Chris Jackson, MD, MS @Chris_JacksonMD]

We at @MSK_RadOnc have already adopted a new cord constraint of D0.1cc &lt; 19.1 Gy in 3 fractions, which is associated with a 1% risk of G3-4 RM 2 years after spine SBRT. This constraint applies to the true cord, or a cord planning organ at risk volume (PRV).

[Adam B. Weiner, MD @Adam_Weiner535]

🚨Testosterone replacement therapy after surgery for #prostatecancer🚨

@JAMAInternalMed

⭐️SPIRIT trial

📊 RCT, n=136, low/int-grade PCa, post-RP, hypogonadal men
⏱️ TRT started ≥2 yrs post-RP w/ undetectable PSA
💉 12 wks testosterone vs placebo
✅ ↑ sexual activity (+0.9 events/day), desire, lean mass, VO₂ peak
🛡️ ZERO biochemical recurrences

⚠️ Short-term, proof-of-concept.
👉Bigger/longer trials including patients with higher-risk disease needed

@PCFnews @PCF_Science @urotoday @renalandurology @UrologyTimes

🔗https://t.co/nPtK3EahPQ

[Dimitrios Tsatiris MD @DrDimitrios]

Becoming a physician is not good for your health.

- High stress
- Sleep disruption
- Intense workload
- Feelings of isolation
- Putting your life on hold
- Limited time for exercise
- Exposure to traumatic cases
- Not having time for family and friends
- Always having to be perfect because the stakes are so high

https://t.co/88TiBA8tBA

[Katy Beckermann @katy_beckermann]

📡 PSMA-PET is more than a staging tool -- it's a survival predictor.

The PPP3 nomograms (Karpinski et al., @TheLancetOncol ) just validated PSMA-PET + PROMISE metrics to prognosticate 3-, 5-, and 7-year OS across ALL prostate cancer stages in 11,154 patients at 35 sites worldwide.

Key signals:
🔹 C-index 0.83-0.84 -- outperforms NCCN, EAU, GAFITA in most subgroups
🔹 No low-risk category for mHSPC, nmCRPC, or mCRPC
🔹 Simplified risk table ready for clinical + trial use
🔹 Free tool: https://t.co/Ug3eQr2S8y

Congrats to the PROMISE Registry team on an extraordinary multi-continent effort 🌍

🔗 https://t.co/IvdmjmmyxM
#ProstateCancer #PSMAPET #GUOnc #Theranostics #LancetOncology #PrecisionOncology

[Inside Skating @insideskating]

#KaoriSakamoto: “One thing that I can say I tried to do, and I did, was: in this world of figure skating, I tried to make a sunnier, brighter atmosphere, so that everybody could compete in a positive way, and looking kind of forward-way”.

Do read: https://t.co/1Kz1ym5fuK

[ASTRO @ASTRO_org]

Check out this new #RedJournal article from @JennKa12 @PaulSargos et al on pushing the boundaries of SBRT in irradiated territories for nodal oligorecurrent prostate cancer. https://t.co/oGMB7Q5Xtk

[Fan Account Doing Team USA Coverage @FanCovTeamUSA]

Kaori Sakamoto wins her fourth World Championship in her final event of her career.

Isabeau Levito will finish fourth and Amber Glenn will finish sixth.

#ISUFigureSkating | #WorldFigure